Executive Summary
small molecules of protein found naturally in the body by VA Kumar·2015·Cited by 179—We design apeptide-based self-assembling nanofibrous hydrogel containing cell-mediated degradation and proangiogenic moieties that specifically address these
Angiogenic peptides are a fascinating class of small molecules of protein found naturally in the body that play a critical role in the formation of new blood vessels, a process known as angiogenesis. This fundamental biological process is essential for numerous physiological functions, including embryonic development, wound healing, and tissue repair. However, the aberrant regulation of angiogenesis is implicated in a wide range of diseases, from cancer to cardiovascular disorders. Consequently, angiogenic peptides are garnering significant attention as potential therapeutic agents.
The scientific community has extensively explored the therapeutic potential of these peptides. Research has demonstrated that pro-angiogenic peptides represent a valuable alternative to traditional drugs for applications in cardiovascular diseases and regenerative medicine. These peptides can promote blood flow and facilitate tissue regeneration, making them promising candidates for treating conditions like ischemia, where blood supply is compromised. For instance, studies have shown that new peptide therapeutic angiogenesis can be achieved in models of ischemic and diabetic conditions, highlighting their capacity to improve blood circulation. Peptide Lv, a newly discovered endogenous angiogenic and vasodilating peptide, has shown promise in promoting angiogenesis and vasodilation, partly through the activation of VEGFR2.
Conversely, the ability of angiogenic peptides to stimulate blood vessel growth also makes them attractive targets for inhibiting pathological angiogenesis. This is particularly relevant in cancer therapy, where tumors rely on a robust blood supply to grow and metastasize. Anti-angiogenic peptides are designed to block this process, thereby starving tumors of nutrients and oxygen. Reviews focusing on anti-angiogenic peptides in the field of cancer therapy showcase efforts in designing, screening, and deriving these molecules from various sources, including nanobodies and phage display libraries. The development of anti-angiogenic protein fragments and peptides is an active area of research, aiming to create therapies with low toxicity and high efficacy. Indeed, Peptides would be a powerful non-immunogenic, anti-angiogenesis therapy, particularly for cancers where specific markers are expressed.
The mechanisms by which angiogenic peptides exert their effects are diverse. Some peptides act as Vascular Endothelial Growth Factor (VEGF) mimetic peptides exerting a pro-angiogenic activity, directly interacting with VEGF receptors to stimulate endothelial cell proliferation and migration. Others, like the RoY peptide, can induce angiogenesis *in vitro* through VEGF-independent mechanisms and promote collateral vessel growth *in vivo*. The development of small peptides able to recognize VEGF receptors is a key strategy in modulating endothelial cell proliferation. Furthermore, Prominin-1 peptides have been designed to modulate angiogenesis using functional endothelial cell assays.
The field of peptide therapeutics is rapidly advancing, with researchers engineering increasingly sophisticated angiogenic peptides. For example, dual-targeting anti-angiogenic cyclic peptides have been developed by combining multiple anti-angiogenic epitopes that act on different pathways of angiogenesis within a single molecular framework. This approach aims to enhance therapeutic efficacy by tackling angiogenesis from multiple angles. Short-peptide biomaterials are also emerging as innovative tools to advance angiogenesis and lymphangiogenesis in regenerative medicine, offering new hope for cardiovascular and other conditions. These short-peptide biomaterials are functional biomaterials that mimic the actions of natural bioactive molecules.
Beyond cancer and cardiovascular diseases, angiogenic peptides have potential applications in other areas. Vasoactive peptides may be directly involved in the pathogenesis of tumor disease through the regulation of angiogenesis, suggesting a complex interplay between these molecules and disease progression. Research into identifying peptides that can block blood vessel growth is ongoing, with libraries of anti-angiogenic peptides being utilized for this purpose. The development of Peptide HRH, a novel peptide specifically binding to VEGF receptor, holds great promise as a therapeutic lead agent for complex angiogenesis-related pathological disorders.
In summary, angiogenic peptides are a versatile class of molecules with significant therapeutic implications. Whether promoting blood vessel formation for tissue regeneration or inhibiting it to combat diseases like cancer, these peptides represent a vital frontier in medical research. The continuous discovery and development of novel angiogenic and anti-angiogenic peptides are poised to revolutionize the treatment of a wide spectrum of human ailments.
Related Articles
Frequently Asked Questions
Here are the most common questions about .
Leave a Comment
Share your thoughts, feedback, or additional insights on this topic.
